Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Kiniksa Pharmaceuticals history
Kiniksa Pharmaceuticals company history timeline
Barry D. Quart, Pharm.D., has served as a director of Kiniksa since October 2015.
Kanuma was approved globally in 2015 as the first therapy for patients suffering from this devastating, often terminal disease.
McCain served as Senior Vice President and Head of Legal of Sanofi Genzyme, a global business unit of Sanofi, from January 2016 to September 2, 2016.
Thomas Malley has served as a director of Kiniksa since December 2016.
Melissa joined Kiniksa in 2017 and has held roles of increasing leadership responsibility since then.
Kimberly J. Popovits has served as a member of our Board of Directors since February 2018.
He took Kiniksa public on the NASDAQ Global Market in May 2018.
He joined Kiniksa prior to the company’s initial public offering in 2018.
Arian has served as Kiniksa’s Senior Vice President of Clinical Development since joining in November of 2019.
Doctor Richard S. Levy has served as director of Kiniksa since early 2019.
FDA grants Breakthrough Therapy designation for rilonacept for recurrent pericarditis and final Phase 2 clinical data presented at the American Heart Association 2019 Scientific Sessions.
G. Bradley Cole has served as a member of our Board of Directors since July 2020.
Rate how well Kiniksa Pharmaceuticals lives up to its initial vision.
Kiniksa Pharmaceuticals jobs
Do you work at Kiniksa Pharmaceuticals?
Does Kiniksa Pharmaceuticals communicate its history to new hires?
Kiniksa Pharmaceuticals competitors
| Company name | Founded date | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Gossamer Bio | 2015 | $114.7M | 100 | 14 |
| Ophthotech | 2007 | $210.0M | 58 | - |
| Homology Medicines | 2015 | ($6.7M) | 124 | - |
| Aurinia Pharmaceuticals | 2013 | $235.1M | 33 | - |
| Onspira Therapeutics | 2017 | $410,000 | 30 | - |
| VERO Biotech | - | $9.7M | 177 | 2 |
| Santarus | 1996 | $218.0M | 290 | - |
| Vyera Pharmaceuticals | 2015 | $5.0M | 175 | - |
| Dova Pharmaceuticals | 2016 | $10.4M | 115 | - |
| Krystal Biotech | 2015 | $290.5M | 37 | 17 |
Kiniksa Pharmaceuticals history FAQs
Zippia gives an in-depth look into the details of Kiniksa Pharmaceuticals, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Kiniksa Pharmaceuticals. The employee data is based on information from people who have self-reported their past or current employments at Kiniksa Pharmaceuticals. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Kiniksa Pharmaceuticals. The data presented on this page does not represent the view of Kiniksa Pharmaceuticals and its employees or that of Zippia.
Kiniksa Pharmaceuticals may also be known as or be related to Kiniksa Pharmaceuticals and Kiniksa Pharmaceuticals, Ltd.